India Adds RO Antiscalants and Biocides to BIS QCO

On June 7, 2026, the Bureau of Indian Standards (BIS) issued a revision that brings RO antiscalants and biocides within the scope of mandatory certification under Quality Control Order (QCO) No. 22. For companies involved in importing, supplying, testing, or purchasing reverse osmosis membrane treatment chemicals for the Indian market, this is a development worth close attention because market access will now be tied not only to BIS ISI marking, but also to local authorized laboratory testing within a defined transition period ending on December 31, 2026.

What the revised requirement confirms

According to the information provided, BIS revised eight quality control orders and formally included RO Antiscalants/Biocides under Mandatory Quality Control Order No. 22. The requirement applies to imports of these products, which must hold BIS ISI mark certification. In addition, the products must complete two tests through locally authorized laboratories: microbial inhibition performance under ISO 20743 and simulated calcium-magnesium scale inhibition rate under ASTM D4582. The transition period runs until December 31, 2026.

Where the impact is most likely to be felt

Import-side compliance becomes a front-end market access issue

From an industry perspective, importers are likely to feel the impact first because the notice directly addresses imported RO antiscalants and biocides. The practical effect is that compliance may shift from a supporting document issue to a precondition for entry into the Indian market. What deserves closer attention is whether existing shipments, product registrations, and sales planning can align with the certification and local testing timeline before the transition period closes.

Manufacturers may need to align product dossiers with test execution

For manufacturers supplying these chemicals into India, the change may affect product documentation, testing coordination, and customer support. Analysis shows that the requirement is not limited to a label or declaration; it also refers to two specific test paths in local authorized laboratories. That makes the connection between formulation claims, technical files, and test readiness more important in actual business execution.

Testing and supply chain service providers may face tighter coordination demands

Service providers involved in regulatory support, customs preparation, laboratory coordination, or delivery scheduling may also be affected. Observably, once local authorized laboratory testing becomes part of the import requirement, timing, document completeness, and communication between overseas suppliers and India-based compliance parties may become more sensitive business steps.

Buyers may pay closer attention to qualification status

Procurement teams and downstream users purchasing RO membrane treatment chemicals for the Indian market may need to review supplier qualification more carefully. The key issue is not only product availability, but whether the supplier can support BIS ISI certification and the required local tests within the applicable transition window.

What companies should watch now

Follow the exact wording of subsequent official notices

What deserves closer attention is the possibility of further clarification in official language, implementation detail, or scope interpretation. Companies should distinguish between the policy signal already visible in the current notice and any later operational guidance that may affect documentation, testing sequence, or product coverage.

Check whether target products fall within the affected category

Businesses selling into India should review whether their RO antiscalants or biocides are positioned, documented, and traded in ways that clearly place them within the newly covered category. This is especially relevant for companies handling multiple water treatment chemical lines where product classification and commercial descriptions may affect compliance handling.

Prepare for dual-test coordination early

Analysis shows that the requirement combines BIS ISI certification with two named tests in locally authorized laboratories. Companies may therefore need to prepare test-related materials, technical records, and communication plans earlier than usual, especially where import schedules or customer delivery commitments extend close to the end of 2026.

Review supplier and customer communication plans

Observably, this type of rule change can quickly move from a regulatory issue to a commercial execution issue. Importers, overseas suppliers, and buyers may all benefit from aligning on certification status, test progress, document readiness, and possible delivery implications during the transition period.

Why this reads as more than a routine revision

Analysis shows that this update is meaningful not simply because another product category has been added to a QCO, but because it links mandatory certification with specific local performance testing for imported RO membrane treatment chemicals. It is more appropriate to understand this as a concrete compliance tightening signal rather than as a completed market outcome. The rule direction is clear in the information provided, but the full business effect will depend on how companies move through certification, testing, and shipment planning over the transition period.

How to interpret the development at this stage

At this stage, the development is best understood as an actionable regulatory change with immediate planning relevance rather than as a conclusion about long-term market restructuring. For affected businesses, the most practical implication is to treat compliance readiness, laboratory coordination, and customer communication as near-term priorities. From an industry perspective, this remains a policy move that warrants continued observation through the end of the transition period and any follow-up implementation details.

Basis of this article

This article is based on the user-provided news title, event date, and event summary concerning the June 7, 2026 BIS revision covering RO antiscalants and biocides under QCO No. 22. For this type of development, commonly relevant source categories may include official notices, company disclosures, industry association updates, authoritative media coverage, and standards-related documents. A specific official source link was not provided in the input, so further verification remains necessary. Continued attention should be paid to any later BIS wording, implementation clarification, and transition-period follow-up that may affect business interpretation.